LICENSE AGREEMENTLicense Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Delaware
WHEREAS, Onconova is developing a pharmaceutical product in the United States under the trademark Estybon™ for use in oncology, and owns or controls certain proprietary technology, know-how and information relating to such product;
EIGHTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTJoinder Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS EIGHTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (this “Agreement”) made as of July 27, 2012, by and among Onconova Therapeutics, Inc., a Delaware corporation (the “Corporation”), the persons listed as owners of Series A Preferred Stock on Schedule I hereto (the “Series A Investors”), the persons listed as owners of Series B Preferred Stock on Schedule I hereto (the “Series B Investors”), the persons listed as owners of Series C Preferred Stock on Schedule I hereto (the “Series C Investors”), the persons listed as owners of Series D Preferred Stock on Schedule I hereto (the “Series D Investors”), the persons listed as owners of Series E Preferred Stock on Schedule I hereto (the “Series E Investors”), the persons listed as owners of Series F Preferred Stock on Schedule I hereto (the “Series F Investors”), the persons listed as owners of Series G Preferred Stock and/or Warrants to purchase Series G Preferred Stock (the “Series G Warrants”) on Schedule I hereto (the “Series G Inve
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations
This Amendment Agreement is made and entered into as of September 1, 2000, by and between Temple University — Of The Commonwealth System of Higher Education (“TEMPLE”) and Onconova Therapeutics Inc. (“ONCONOVA”).
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into on this 19th day of September, 2012 (the “Effective Date”), by and between Onconova Therapeutics, Inc., a company organized under the laws of the State of Delaware with its principal place of business at 375 Pheasant Run, Newtown, PA 18490 (“Onconova”) and Baxter Healthcare SA, a company organized under the laws of the Switzerland with its principal place of business at Thurgauerstrasse 130 8152 Glattpark (Opfikon) Switzerland (“Baxter”). Onconova and Baxter may each be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO AGREEMENTTo Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Agreement, effective June 23, 2011, is by and between THE LEUKEMIA & LYMPHOMA SOCIETY (“LLS”), a Delaware corporation, business at 1311 Mamaroneck Ave, White Plains, NY and ONCONOVA THERAPEUTICS (“ONCONOVA”), a Delaware corporation having its principal place of business at 375 Pheasant Run, Newtown, PA.
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is entered into effective as of September 2, 2011, by and between Onconova Therapeutics, Inc, (“Onconova”), and SymBio Pharmaceuticals Limited (“SymBio”) (each, a “Party” and together, “the “Parties”), with respect to the following facts:
CONSULTING AGREEMENTConsulting Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
THIRD AMENDMENT TO DEFINITIVE AGREEMENTDefinitive Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment to Agreement, effective January 15, 2013, is by and between THE LEUKEMIA & LYMPHOMA SOCIETY (“LLS”), a Delaware corporation, business at 1311 Mamaroneck Ave, White Plains, NY and ONCONOVA THERAPEUTICS (“ONCONOVA”), a Delaware corporation having its principal place of business at 375 Pheasant Run, Newtown, PA.
SECOND AMENDMENT TO DEFINITIVE AGREEMENTDefinitive Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to Definitive Agreement, effective May 29, 2012, is by and between THE LEUKEMIA & LYMPHOMA SOCIETY (“LLS”), a New York non-profit corporation, having its principal place of business at 1311 Mamaroneck Ave, White Plains, NY and ONCONOVA THERAPEUTICS, INC. (“ONCONOVA,” or “Company”), a Delaware corporation having its principal place of business at 375 Pheasant Run, Newtown, PA.
TERMINATION OF AGREEMENTTermination of Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations
This Termination of Agreement, effective February 5, 2013, is by and between THE LEUKEMIA & LYMPHOMA SOCIETY (“LLS”), a Delaware corporation, having its principal place of business at 1311 Mamaroneck Ave, White Plains, NY and ONCONOVA THERAPEUTICS (“ONCONOVA,” together “the Parties”), a Delaware corporation having its principal place of business at 375 Pheasant Run, Newtown, PA.
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. LICENSE AGREEMENTLicense Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This agreement (the “License Agreement”) is made effective this first day of January, 1999 by and between Temple University - Of The Commonwealth System of Higher Education, a corporation organized and existing under the laws of the Commonwealth of Pennsylvania (“TEMPLE”), having a principal place of business at Broad Street and Montgomery Avenue, Philadelphia, Pennsylvania and Onconova Therapeutics Inc. (“ONCONOVA”), a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at P.O. Box 7693, Princeton, New Jersey.
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. DEFINITIVE AGREEMENTDefinitive Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
This Definitive Agreement (the “Agreement”) is made as of the 12th day of May, 2010 (the “Effective Date”) by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Onconova Therapeutics, Inc., a Delaware corporation with its principal place of business at 375 Pheasant Run, Newtown, PA 18940 (“Company”). LLS and Company are sometimes hereinafter referred to individually as the “Party” and together as the “Parties”.
AMENDMENT # 1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 3rd, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment No. 1”) to the License Agreement by and between Temple University — Of The Commonwealth System of Higher Education (“TEMPLE”) and Onconova Therapeutics (“ONCONOVA”), dated January 1, 1999, as amended (“Agreement”), is entered into effective as of March 21, 2013 (“Amendment No. 1 Date”).
